FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The basic challenge faced by medical products companies is that they’re trying to sell expensive products into an environment that’s increasing concerned about the cost of care, and in which key stakeholders are aggressively looking for opportunities to bring the costs down, and avoid unnecessary expenditures.
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.
As drug companies take divergent strategies focused either on research or cutting costs, what might this mean for the path future companies take in the pharmaceutical industry?
High-profile technology companies are revered by society while pharmaceutical companies developing life-saving technologies are viewed with contempt; why the disparity?
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
Scott Gottlieb's testimony for the House Energy and Commerce Committee, Subcommittee on Health's hearing on drug compounding.
Drug companies -- at least every one that I've worked with -- would like to develop important new medicines that improve health and save lives. That's what gets every industry researcher I know up in the morning, and what keeps them going through the many highs and lows that characterize the scientific process.
At this event, Dinesh Thakur will discuss his experiences and the wider problems of Indian drug quality. Pharmaceutical and medical experts will then discuss Thakur’s remarks and the safety of US and international drugs.
Join us for a conversation with Governor Dannel Malloy as he discusses the successes and challenges of accomplishing school reform at the state level.
Join AEI in welcoming Michael Rubin for a Bradley Lecture discussing his upcoming book “Dancing with the devil: Lessons from negotiating with rogues and terrorists.”
At the Philanthropic Freedom Project's inaugural public event, AEI President Arthur Brooks will present his new research on how charitable giving has changed in the United States in the wake of the Great Recession and how those changes have serious ramifications for future tax policy.
The Air Force Association’s Mitchell Institute and AEI’s Marilyn Ware Center for Security Studies invite you to a forum with the 18th Air Force Chief of Staff General T. Michael Moseley (ret.) to discuss the imperative for air power in an increasingly uncertain world.
Thie event will address the economic implications of cultural fragmentation, the perception of capitalism in Western culture, and how economists can incorporate cultural considerations into their analyses.